載入中
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.
前收盤價
US$3.08
−US$0.05 · -1.60%
盤中時間採用ET。市場資料可能有所延遲。
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.
日內區間
目前US$3.08
52週區間
目前US$3.08
盤中時間採用ET。市場資料可能有所延遲。
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.
日內區間
目前US$3.08
52週區間
目前US$3.08
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 59.01萬 USD | 246.73萬 USD | — | 76.63萬 USD | 827 USD |
| 銷貨成本 | 51.53萬 USD | 67.02萬 USD | 554 USD | 31.9萬 USD | 88 USD |
| 毛利 | 7.48萬 USD | 179.71萬 USD | −554 USD | 44.73萬 USD | 739 USD |
| 研究與開發 | 14.7萬 USD | 10.47萬 USD | 7410 USD | 22.87萬 USD | 12.36萬 USD |
| 銷售、一般及管理費用 | 162.4萬 USD | 85.58萬 USD | 113.3萬 USD | 172.94萬 USD | 63.43萬 USD |
| 營業費用 | 745.15萬 USD | 366.36萬 USD | 114.04萬 USD | 223.56萬 USD | 78.58萬 USD |
| 利息收入 | 11.8萬 USD | 1.29萬 USD | 5564 USD | 7702 USD | — |
| 利息支出 | 54.71萬 USD | 73.52萬 USD | — | 2629 USD | — |
| 折舊和攤銷 | 11.05萬 USD | 1.3萬 USD | 1.16萬 USD | 6512 USD | 2757 USD |
| 營業利益 | −737.67萬 USD | −186.66萬 USD | −114.1萬 USD | −178.83萬 USD | −78.51萬 USD |
| 淨利 | −770.81萬 USD | −624.57萬 USD | −430.15萬 USD | −180.03萬 USD | −78.47萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年8月21日 | 1:10 | — | — |
股票分割 | 2026年3月10日 | 1:6 | — | — |
股票分割 | 2026年1月6日 | 1:4 | — | — |
股票分割 | 2025年9月2日 | 2:7 | — | — |
股票分割 | 2025年3月10日 | 1:7 | — | — |
股票分割 | 2024年11月27日 | 1:200 | — | — |
已生效 2026年8月21日
1:10
已生效 2026年3月10日
1:6
已生效 2026年1月6日
1:4
已生效 2025年9月2日
2:7
已生效 2025年3月10日
1:7
已生效 2024年11月27日
1:200
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
